Adoptive T-cell Therapy for Hematological Malignancies Using T Cells Gene-modified to Express Tumor Antigen-specific Receptors

Overview

Journal Int J Hematol

Specialty Hematology

Date 2013 Dec 20

PMID 24352938

Citations 7

Authors

Hiroshi Fujiwara

Affiliations

Soon will be listed here.

Abstract

The functional properties of the adoptive immune response mediated by effector T lymphocytes are decisively regulated by their T-cell receptors (TCRs). Transfer of genes encoding target antigen-specific receptors enables polyclonal T cells to redirect toward cancer cells and virally infected cells expressing those defined antigens. Using this technology, a large population of redirected T cells displaying uniform therapeutic properties has been produced, powerfully advancing their clinical application as "cellular drugs" for adoptive immunotherapy against cancer. Clinically, anticancer adoptive immunotherapy using these genetically engineered T cells has an impressive and proven track record. Notable examples include the dramatic benefit of chimeric antigen receptor gene-modified T cells redirected towards B-cell lineage antigen CD19 in patients with chronic lymphocytic leukemia, and the impressive outcomes in the use of TCR gene-modified T cells redirected towards NY-ESO-1, a representative cancer-testis antigen, in patients with advanced melanoma and synovial cell sarcoma. In this review, we briefly overview the current status of this treatment option in the context of hematological malignancy, and discuss a number of challenges that still pose an obstacle to the full effectiveness of this strategy.

Citing Articles

Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.

Xiang X, He Q, Ou Y, Wang W, Wu Y Front Pharmacol. 2020; 11:544754.

PMID: 33343342 PMC: 7744881. DOI: 10.3389/fphar.2020.544754.

T cell receptor-engineered T cells for leukemia immunotherapy.

Zhang Y, Li Y Cancer Cell Int. 2019; 19:2.

PMID: 30622438 PMC: 6317187. DOI: 10.1186/s12935-018-0720-y.

Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system.

Han W, Li W, Zhang X, Du Z, Liu X, Zhao X Oncotarget. 2017; 8(9):15034-15046.

PMID: 28122343 PMC: 5362465. DOI: 10.18632/oncotarget.14746.

Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.

Zha X, Xu L, Chen S, Yang L, Zhang Y, Lu Y Oncotarget. 2016; 7(51):84246-84257.

PMID: 27713165 PMC: 5356659. DOI: 10.18632/oncotarget.12441.

Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

Tani K Int J Hematol. 2016; 104(1):42-72.

PMID: 27289360 DOI: 10.1007/s12185-016-2030-2.

References

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Warren E, Fujii N, Akatsuka Y, Chaney C, Mito J, Loeb K . Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood. 2010; 115(19):3869-78. PMC: 2869557. DOI: 10.1182/blood-2009-10-248997. View

Irving B, Weiss A . The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991; 64(5):891-901. DOI: 10.1016/0092-8674(91)90314-o. View

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

Gong M, Latouche J, Krause A, Heston W, Bander N, Sadelain M . Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 2000; 1(2):123-7. PMC: 1508130. DOI: 10.1038/sj.neo.7900018. View

Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M . Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010; 18(4):666-8. PMC: 2862525. DOI: 10.1038/mt.2010.31. View

Savoldo B, Ramos C, Liu E, Mims M, Keating M, Carrum G . CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011; 121(5):1822-6. PMC: 3083795. DOI: 10.1172/JCI46110. View

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View

10.

Thomas S, Xue S, Cesco-Gaspere M, San Jose E, Hart D, Wong V . Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol. 2007; 179(9):5803-10. DOI: 10.4049/jimmunol.179.9.5803. View

11.

Kolb H, Schmid C, Barrett A, Schendel D . Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2003; 103(3):767-76. DOI: 10.1182/blood-2003-02-0342. View

12.

Haynes N, Trapani J, Teng M, Jackson J, Cerruti L, Jane S . Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 2002; 169(10):5780-6. DOI: 10.4049/jimmunol.169.10.5780. View

13.

Chmielewski M, Hombach A, Heuser C, Adams G, Abken H . T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004; 173(12):7647-53. DOI: 10.4049/jimmunol.173.12.7647. View

14.

Li Y, Moysey R, Molloy P, Vuidepot A, Mahon T, Baston E . Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005; 23(3):349-54. DOI: 10.1038/nbt1070. View

15.

Pagliara D, Savoldo B . Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients. Curr Opin Infect Dis. 2012; 25(4):431-7. DOI: 10.1097/QCO.0b013e3283551dd3. View

16.

Rohon P . Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol. 2012; 96(1):1-9. DOI: 10.1007/s12185-012-1116-8. View

17.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

18.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

19.

Maus M, Haas A, Beatty G, Albelda S, Levine B, Liu X . T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2014; 1(1):26-31. PMC: 3888798. DOI: 10.1158/2326-6066.CIR-13-0006. View

20.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View